The American pharmaceutical group Johnson & Johnson (J&J) anticipates for 2021 the sale of 2.5 billion dollars of anti-Covid vaccines and, taking advantage of the resumption of non-urgent medical procedures, raised its forecasts for the whole of the year.
This is relatively small compared to sales of the coronavirus vaccines from Moderna or Pfizer, the latter having planned in May to sell it for $ 26 billion worldwide this year.
Read also: Europe's green light for Johnson & Johnson vaccine
Urgently approved in the United States last February, J & J's vaccine suffered several setbacks, including a ten-day suspension in April after women were reported to have developed severe cases of blood clots, and production problems at a factory. in Baltimore.
In the second quarter, the group benefited in any case from the vaccination campaigns against Covid, which allowed the return of non-urgent procedures and the resumption of sales of medical devices such as prostheses.
The latter jumped 62.7%.
Profits on the rise
The total turnover of the company, which also includes its pharmaceutical division (+ 17.2%) and its division of personal hygiene and health products such as creams and dressings (+ 13.3% ), increased by 27.1%.
J&J now expects sales of between 91.3 and 92.1 billion dollars in 2021 (93.8 and 94.6 billion including sales of the anti-Covid vaccine), against a range of between 90.6 and 91.6 billion previously.
To read also: Vaccination: deliveries of Pfizer down and AstraZeneca shunned by the French
The group also saw its net profit soar 73% to 6.28 billion dollars in the second quarter. Reported per share and excluding exceptional items, it appears at 2.48 dollars, against 2.27 expected by analysts. For the year as a whole, the group expects an adjusted profit of between 9.60 and 9.70 dollars, against 9.42 and 9.57 dollars previously. The title took 1.2% in electronic trading preceding the opening of the official session on Wall Street.